Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation-Reference-Cited by-同舟云学术

Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation

Published:2021-04 Issue:4 Volume:24 Page:102298
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Ganneru Brunda,Jogdand Harsh,Daram Vijaya Kumar^ORCID,Das Dipankar,Molugu Narasimha Reddy,Prasad Sai D.^ORCID,Kannappa Srinivas V.,Ella Krishna M.,Ravikrishnan Rajaram,Awasthi Amit,Jose Jomy^ORCID,Rao Panduranga,Kumar Deepak,Ella Raches^ORCID,Abraham Priya,Yadav Pragya D.,Sapkal Gajanan N.,Shete-Aich Anita,Desphande Gururaj,Mohandas Sreelekshmy,Basu Atanu,Gupta Nivedita,Vadrevu Krishna Mohan

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference48 articles.

1. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine;Keech;N. Engl. J. Med.,2020

2. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls;Le Bert;Nature,2020

3. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial;Bhandari;Lancet Lond. Engl.,2014

4. COVID-19 makes B cells forget, but T cells remember;Cañete;Cell,2020

5. NewDrugs CTRules 2019;CDSCO,2019

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals;Scientific Reports;2024-07-24

2. Elucidating the Immune Response to SARS-CoV-2: Natural Infection versus Covaxin/Covishield Vaccination in a South Indian Population;Viruses;2024-07-23

3. Design and Synthesis of Polyphenolic Imidazo[4,5-c]quinoline Derivatives to Modulate Toll Like Receptor-7 Agonistic Activity and Adjuvanticity;ACS Pharmacology & Translational Science;2024-06-12

4. Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections;Vaccines;2024-04-29

5. The scientific journey of a novel adjuvant (AS37) from bench to bedside;npj Vaccines;2024-02-08